Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/85555
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer
Author: Short, M.
Goldstein, D.
Halkett, G.
Reece, W.
Borg, M.
Zissiadis, Y.
Kneebone, A.
Spry, N.
Citation: International Journal of Radiation Oncology, Biology, Physics, 2013; 85(1):157-162
Publisher: Elsevier Science
Issue Date: 2013
ISSN: 0360-3016
1879-355X
Statement of
Responsibility: 
Michala Short, David Goldstein, Georgia Halkett, William Reece, Martin Borg, Yvonne Zissiadis, Andrew Kneebone, and Nigel Spry
Abstract: <h4>Purpose</h4>To report quality of life (QOL) results for patients receiving chemoradiation therapy for pancreatic cancer.<h4>Methods and materials</h4>Eligible patients (n=41 locally advanced, n=22 postsurgery) entered the B9E-AY-S168 study and received 1 cycle of induction gemcitabine (1000 mg/m2 weekly ×3 with 1-week break) followed by 3-dimensional conformal radiation therapy (RT) (54 Gy locally advanced and 45 Gy postsurgery) and concomitant continuous-infusion 5-fluorouracil (5FU) (200 mg/m2/d throughout RT). After 4 weeks, patients received an additional 3 cycles of consolidation gemcitabine chemotherapy. Patients completed the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-PAN26 questionnaires at baseline, before RT/5FU, at end of RT/5FU, before consolidation gemcitabine, and at treatment completion.<h4>Results</h4>The patterns of change in global QOL scores differed between groups. In the locally advanced group global QOL scores were +13, +8, +3, and +1 compared with baseline before RT/5FU (P=.008), at end of RT/5FU, before consolidation gemcitabine, and at treatment completion, respectively. In the postsurgery group, global QOL scores were -3, +4, +15, and +17 compared with baseline at the same time points, with a significant improvement in global QOL before consolidation gemcitabine (P=.03). No significant declines in global QOL were reported by either cohort.<h4>Conclusions</h4>This study demonstrates that global QOL and associated function and symptom profiles for pancreatic chemoradiation therapy differ between locally advanced and postsurgery patients, likely owing to differences in underlying disease status. For both groups, the treatment protocol was well tolerated and did not have a negative impact on patients' global QOL.
Keywords: Humans; Adenocarcinoma; Pancreatic Neoplasms; Fluorouracil; Deoxycytidine; Antimetabolites, Antineoplastic; Radiation-Sensitizing Agents; Treatment Outcome; Radiotherapy, Conformal; Prospective Studies; Quality of Life; Adult; Aged; Middle Aged; Female; Male; Chemoradiotherapy; Induction Chemotherapy; Surveys and Questionnaires
Rights: © 2014 Elsevier Inc. All rights reserved.
RMID: 0020137498
DOI: 10.1016/j.ijrobp.2012.03.003
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.